Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy

Allergy, Asthma & Clinical Immunology 2017, 13:45 | Published on: 3 November 2017

I. J. Pouliquen, P. Howarth, D. Austin, G. Gunn, E. Meyer, R. G. Price and E. Bradford

To the Editor,

We read with interest the case report and accompanying discussion published by Mukherjee et al. (AACI 2017;13:2) of a 62-year old woman diagnosed with severe eosinophilic asthma. This clinical case presents a patient with progressive deterioration in FEV1 function since 2011 with no improvement observed while receiving OCS, hydroxyurea or imatinib therapy. On this background of deterioration, the patient entered the double-blind placebo controlled clinical trial MEA115575 and received mepolizumab 100 mg s.c. every 4 weeks. Further deterioration in FEV1 coincided with the (protocol defined) reduction in prednisolone during the study, and neither intravenous solumedrol nor pre-study prednisolone doses improved FEV1 to pre-study values. During the open-label mepolizumab extension study MEA115661 the patient’s clinical status was unchanged. In January 2015, 9 months after their last dose of mepolizumab, the patient further deteriorated whilst receiving azathioprine immunosuppressive therapy. This clinical case presentation clearly underlines the aggressive nature...

 

Full Text | PDF

 

 

 

 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: Vitamin D, the Sunshine Supplement, Has Shadowy Money Behind It https://t.co/wOlRsBJDir, see more https://t.co/CpGiFuOOYd
3hreplyretweetfavorite
Interasma Interasma - Secondhand Smoke Exposure in Childhood and Adulthood in Relation to Adult Mortality Among Never Smokers https://t.co/OiRAEbm3ti
5hreplyretweetfavorite
Interasma Interasma - Age and African-American race impact the validity and reliability of the asthma control test in persist… https://t.co/uwJyO07bis
5hreplyretweetfavorite
Interasma RT @Aller_MD: Autoinjectors are in especially high demand as the new school year begins. Reports of a shortage of EpiPens have been surfaci…
16hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: Child passive smoking 'increases chronic lung risk' - BBC News https://t.co/nga9azowZF, see more https://t.co/jgCe
16hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma